• Home
  • About
  • Approach
  • Pipeline
  • News & Resources
  • Contact
Menu
  • Home
  • About
  • Approach
  • Pipeline
  • News & Resources
  • Contact

News & Resources

AllVideo & PresentationsPress ReleasesPublications

Press Releases

Scopus BioPharma’s Subsidiary — Duet BioTherapeutics — Announces Key Scientific Data to be Presented at the 37th Annual Meeting and Exposition of the Society for Immunotherapy of Cancer

November 10, 2022

Read more

Press Releases

Scopus Biopharma Completes Recapitalization Designed To Enhance Shareholder Value

October 18, 2022

Read more

Press Releases

Scopus BioPharma’s Subsidiary — Duet BioTherapeutics — to Present at the 3rd Annual STING & TLR-Targeting Therapies Summit

March 22, 2022

Read more

Video & Presentations

https://duettx.com/wp-content/uploads/Scopus-BioPharma-Presentation-on-Launch-of-Duet-Therapeutics-at-H.C.-Wainwright-23rd-Annual-Global-Investment-Conference.mp4
Featured Video Play Icon

Scopus Presentation on Launch of Duet Therapeutics, its Wholly-Owned Subsidiary Focused on Immuno-Oncology

October 7, 2021

Read more

Press Releases

Scopus BioPharma to Present at the LD Micro Main Event

October 5, 2021

Read more

Press Releases

Scopus BioPharma to Present at MicroCap Rodeo’s Fall Harvest Best Ideas Conference

October 1, 2021

Read more

Press Releases

Scopus BioPharma's Subsidiary — Duet Therapeutics — Announces Release of Preclinical Data Being Presented at 17th Annual Meeting of the Oligonucleotide Therapeutics Society

September 29, 2021

Read more

Press Releases

Scopus BioPharma’s Subsidiary — Duet Therapeutics — Set to Release Scientific Data During the 17th Annual Meeting of the Oligonucleotide Therapeutics Society

September 28, 2021

Read more

Video & Presentations

https://duettx.com/wp-content/uploads/Duet-Therapeutics-a-Scopus-BioPharma-Company-Mechanism-of-Action.mp4
Featured Video Play Icon

Duet Therapeutics, a Scopus BioPharma Company (Mechanism of Action)

September 27, 2021

Read more

Press Releases

Scopus BioPharma to Present at the Benzinga Healthcare Small Cap Conference

September 23, 2021

Read more

Press Releases

Scopus BioPharma's Subsidiary — Duet Therapeutics — to Present at the 17th Annual Meeting of the Oligonucleotide Therapeutics Society

September 22, 2021

Read more

Press Releases

China National Intellectual Property Administration Grants New Patent Covering DUET-02, One of Three Key CpG-STAT3 Inhibitors Comprising the Duet Platform

September 21, 2021

Read more

Press Releases

Scopus BioPharma’s Subsidiary — Duet Therapeutics — Announces Appointments of John Rossi, Ph.D. and Nagy Habib, Ch.M., F.R.C.S. to the Scientific Advisory Board

September 14, 2021

Read more

Press Releases

Scopus BioPharma to Present at H.C. Wainwright 23rd Annual Global Investment Conference

September 9, 2021

Read more

Press Releases

Scopus BioPharma’s Subsidiary — Duet Therapeutics — Announces Appointment of Marcin Kortylewski, Ph.D. as Senior Scientific Advisor

September 7, 2021

Read more

Press Releases

Scopus BioPharma’s Subsidiary — Duet Therapeutics — to Present at the 14th Annual RNA Consortium Meeting

September 3, 2021

Read more

Press Releases

Scopus BioPharma Launches Duet Therapeutics

September 2, 2021

Read more

Press Releases

Scopus BioPharma Announces New Management Appointment Following Acquisition of Leading Immunotherapy Company

July 12, 2021

Read more

Press Releases

Scopus BioPharma Expands Immunotherapy Pipeline with Acquisition of Olimmune

June 30, 2021

Read more

Publications

Myeloid cell-targeted STAT3 inhibition sensitizes head and neck cancers to radiotherapy and T cell-mediated immunity

Journal of Clinical Investigation

November 24, 2020

Dayson Moreira, Sagus Sampath, Haejung Won, Seok Voon White, Yu-Lin Su, Marice Alcantara, Chongkai Wang, Peter Lee, Elli Maghami, Erminia Massarelli, & Marcin Kortylewski

Read more

Publications

STAT3 inhibition combined with CpG immunostimulation activates antitumor immunity to eradicate genetically distinct castration-resistant prostate cancers

Clinical Cancer Research

December 1, 2018

Dayson Moreira, Tomasz Adamus, Xingli Zhao, Yu-Lin Su, Zhuoran Zhang, Seok Voon White, Piotr Swiderski, Xin Lu, Ronald DePinho, Sumanta Pal, & Marcin Kortylewski

Read more

Publications

B cell lymphoma immunotherapy using TLR9-targeted oligonucleotide STAT3 inhibitors

Molecular Therapy

January 15, 2018

Xingli Zhao, Zhuoran Zhang, Dayson Moreira, Yu-Lin Su, Haejung Won, Tomasz Adamus, Zhenyuan Dong, Yong Liang, Hongwei Yin, Piotr Swiderski, Raju Pillai, Larry Kwak, Stephen Forman, & Marcin Kortylewski

Read more

Publications

Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities

Cancer Immunology, Immunotherapy

February 18, 2017

Marcin Kortylewski & Dayson Moreira

Read more

Publications

Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia

Blood

March 31, 2016

Qifang Zhang, Dewan Md Sakib Hossain, Priyanka Duttagupta, Dayson Moreira, Xingli Zhao, Haejung Won, Ralf Buettner, Sergey Nechaev, Marcin Majka, Bin Zhang, Qi Cai, Piotr Swiderski, Ya-Huei Kuo, Stephen Forman, Guido Marcucci, Marcin Kortylewski

Read more

Publications

TLR9-targeted STAT3 silencing abrogates immunosuppressive activity of myeloid-derived suppressor cells from prostate cancer patients

Clinical Cancer Research

August 15, 2015

Dewan M. S. Hossain, Sumanta K. Pal, Dayson Moreira, Priyanka Duttagupta, Qifang Zhang, Haejung Won, Jeremy Jones, Massimo D'Apuzzo, Stephen Forman, and Marcin Kortylewski

Read more

Publications

Revisiting STAT3 signalling in cancer: new and unexpected biological functions

Nature Reviews Cancer

October 24, 2014

Hua Yu, Heehyoung Lee, Andreas Herrmann, Ralf Buettner, & Richard Jove

Read more

Publications

Leukemia cell-targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity

Blood

January 2, 2014

Dewan Md Sakib Hossain, Cedric Dos Santos, Qifang Zhang, Anna Kozlowska, Hongjun Liu, Chan Gao, Dayson Moreira, Piotr Swiderski, Agnieszka Jozwiak, Justin Kline, Stephen Forman, Ravi Bhatia, Ya-Huei Kuo, Marcin Kortylewski

Read more

Publications

TLR9 signaling in the tumor microenvironment initiates cancer recurrence after radiation therapy

Cancer Research

December 1, 2013

Chan Gao, Anna Kozlowska, Sergey Nechaev, Haiqing Li, Qifang Zhang, Dewan M S Hossain, Claudia M Kowolik, Peiguo Chu, Piotr Swiderski, Don J Diamond, Sumanta K Pal, Andrew Raubitschek, Marcin Kortylewski

Read more

Publications

Intracellular processing of immunostimulatory CpG-siRNA: toll-like receptor 9 facilitates siRNA dicing and endosomal escape

Science Direct

September 28, 2013

Sergey Nechaev, Chan Gao, Dayson Moreira, Piotr Swiderski, Agnieszka Jozwiak, Claudia M Kowolik, Jiehua Zhou, Brian Armstrong, Andrew Raubitschek, John J Rossi, Marcin Kortylewski

Read more

Publications

TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo

Blood

February 21, 2013

Qifang Zhang, Dewan Md Sakib Hossain, Sergey Nechaev, Anna Kozlowska, Wang Zhang, Yong Liu, Claudia M Kowolik, Piotr Swiderski, John J Rossi, Stephen Forman, Sumanta Pal, Ravi Bhatia, Andrew Raubitschek, Hua Yu, Marcin Kortylewski

Read more

Publications

STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors

Nature Medicine

November 21, 2010

Heehyoung Lee, Jiehui Deng, Maciej Kujawski, Chunmei Yang, Yong Liu, Andreas Herrmann, Marcin Kortylewski, David Horne, George Somlo, Stephen Forman, Richard Jove, Hua Yu

Read more

Publications

Targeting STAT3 in the myeloid compartment drastically improves the in vivo antitumor functions of adoptively transferred T cells

Cancer Research

October 1, 2010

Andreas Herrmann, Marcin Kortylewski, Maciej Kujawski, Chunyan Zhang, Karen Reckamp, Brian Armstrong, Lin Wang, Claudia Kowolik, Jiehui Deng, Robert Figlin, Hua Yu

Read more

Publications

STATs in cancer inflammation and immunity: a leading role for STAT3

Nature Reviews Cancer

November 1, 2009

Hua Yu, Drew Pardoll, Richard Jove

Read more

Publications

TLR agonist-STAT3 siRNA conjugates: cell-specific gene silencing and enhanced antitumor immune responses

Nature Biotechnology

September 13, 2009

Marcin Kortylewski, Piotr Swiderski, Andreas Herrmann, Lin Wang, Claudia Kowolik, Maciej Kujawski, Heehyoung Lee, Anna Scuto, Yong Liu, Chunmei Yang, Jiehui Deng, Harris S Soifer, Andrew Raubitschek, Stephen Forman, John J Rossi, Drew Pardoll, Richard Jove, & Hua Yu

Read more

Publications

TLR9 activation of STAT3 constrains its agonist-based immunotherapy

Cancer Research

March 3, 2009

Marcin Kortylewski, Maciej Kujawski, Andreas Herrmann, Chunmei Yang, Lin Wang, Yong Liu, Rosalba Salcedo, and Hua Yu

Read more

Publications

Regulation of the IL-23 and IL-12 balance by STAT3 signaling in the tumor microenvironment

Cancer Cell

February 3, 2009

Marcin Kortylewski, Hong Xin, Maciej Kujawski, Heehyoung Lee, Yong Liu, Timothy Harris, Charles Drake, Drew Pardoll, Hua Yu

Read more

Publications

Crosstalk between cancer and immune cells: role of STAT3 in the tumor microenvironment

Nature Reviews Immunology

January 1, 2007

Hua Yu, Marcin Kortylewski, & Drew Pardoll

Read more

Publications

Inhibiting STAT3 signaling in the hematopoietic system elicits multicomponent antitumor immunity

Nature Medicine

November 20, 2005

Marcin Kortylewski, Maciej Kujawski, Tianhong Wang, Sheng Wei, Shumin Zhang, Shari Pilon-Thomas, Guilian Niu, Heidi Kay, James Mulé, William G Kerr, Richard Jove, Drew Pardoll & Hua Yu

Read more

Publications

Regulation of the innate and adaptive immune responses by Stat3 signaling in tumor cells

Nature Medicine

December 21, 2003

Tianhong Wang, Guilian Niu, Marcin Kortylewski, Lyudmila Burdelya, Kenneth Shain, Shumin Zhang, Raka Bhattacharya, Dmitry Gabrilovich, Richard Heller, Domenico Coppola, William Dalton, Richard Jove, Drew Pardoll, Hua Yu

Read more
  • Home
  • About
  • Approach
  • Pipeline
  • News & Resources
  • Contact
Menu
  • Home
  • About
  • Approach
  • Pipeline
  • News & Resources
  • Contact

© 2023 Duet BioTherapeutics. All rights reserved | Privacy Policy | Cookies Policy